What is Causaly?
Causaly is at the forefront of redefining human discovery by leveraging transformative AI technologies. Established in 2018, the company's proprietary AI platform serves as a critical tool for modern Life Science research organizations. It fundamentally reshapes how data is discovered, analyzed, and applied, thereby accelerating decision-making processes in drug discovery and development. Causaly's innovative solutions are designed to unlock new insights from complex biological data, empowering researchers to overcome critical challenges in bringing new therapies to market.
How much funding has Causaly raised?
Causaly has raised a total of $81.8M across 3 funding rounds:
Series A
$4.8M
Unspecified
$17M
Series B
$60M
Series A (2019): $4.8M with participation from Ebrd Vcip, Marathon Venture Capital, and Pentech Ventures
Unspecified (2021): $17M led by EBRD, Index Ventures, Pentech, and Marathon
Series B (2023): $60M supported by Pentech, Marathon Venture Capital, ICONIQ Growth, and Index Ventures
Key Investors in Causaly
Ebrd Vcip
EBRD Venture Capital is a venture capital firm specializing in technology sector investments, headquartered in London, United Kingdom.
Marathon Venture Capital
Marathon Venture Capital is a seed-stage fund focused on supporting ambitious Greek and European founders in building world-class technology companies, with a particular interest in AI, security, and biopharma.
ICONIQ Growth
ICONIQ Growth partners with visionary entrepreneurs to build enduring companies, leveraging its ecosystem to amplify portfolio success from early growth stages through IPO.
What's next for Causaly?
With the infusion of $60M in its latest major strategic investment, Causaly is poised for accelerated expansion and further development of its AI-driven research platform. This enterprise-level backing suggests a focus on scaling operations, enhancing its technological capabilities, and broadening its market reach within the global Life Science sector. The company's strategic capital raises indicate a strong market validation and a clear path towards solidifying its position as a leader in AI-powered drug discovery and development, aiming to significantly shorten research timelines and improve therapeutic outcomes.
See full Causaly company page
